Cover Image

Nrf2 Mitigates RANKL and M-CSF Induced Osteoclast Differentiation via ROS-Dependent Mechanisms

Nuclear factor-erythroid 2-related factor 2 (Nrf2) has been shown to be a negative regulator of osteoclast differentiation, but the precise mechanisms have not yet been established. We examined the precise roles of Nrf2 in regulating antioxidants and reactive oxygen species (ROS) levels, especially...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yang Yang (Author), Zhiyuan Liu (Author), Jinzhi Wu (Author), Simeng Bao (Author), Yanshuai Wang (Author), Jiliang Li (Author), Tao Song (Author), Yongxin Sun (Author), Jingbo Pi (Author)
Format:	Book
Published:	MDPI AG, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
by: Jianbo He, et al.
Published: (2021)

Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity
by: Jianbo He, et al.
Published: (2023)

CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways
by: Jing Li, et al.
Published: (2022)

Plumbagin modulates RANKL-induced osteoclast and osteoblast differentiation
by: Soni Ghumnani, et al.
Published: (2023)

Flavopiridol Protects Bone Tissue by Attenuating RANKL Induced Osteoclast Formation
by: Zi'ang Hu, et al.
Published: (2018)

α-1 Antitrypsin Inhibits RANKL-induced Osteoclast Formation and Functions
by: Mohammad Ahsanul Akbar, et al.
Published: (2017)

Osteoclast activity in osteoporosis mandibular bone based on RANKL and osteoprotegerin ratio.
by: Mefina Kuntjoro, et al.
Published: (2021)

Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
by: Guobin Qi, et al.
Published: (2022)

Artemisinic acid attenuates osteoclast formation and titanium particle-induced osteolysis via inhibition of RANKL-induced ROS accumulation and MAPK and NF-κB signaling pathways
by: Tian Gao, et al.
Published: (2024)

Angelicin improves osteoporosis in ovariectomized rats by reducing ROS production in osteoclasts through regulation of the KAT6A/Nrf2 signalling pathway
by: Xiao-feng Liu, et al.
Published: (2024)

Fisetin Inhibits Osteoclastogenesis Through Prevention of RANKL-Induced ROS Production by Nrf2-Mediated Up-regulation of Phase II Antioxidant Enzymes
by: Eiko Sakai, et al.
Published: (2013)

Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression
by: Eun-Jung Kim, et al.
Published: (2018)

The RANKL expression and osteoclast in alveolar bone of rat diabetic model at different mechanical force application
by: Nuzulul Hikmah, et al.
Published: (2018)

Fumitremorgin C Attenuates Osteoclast Formation and Function via Suppressing RANKL-Induced Signaling Pathways
by: Yu Yuan, et al.
Published: (2020)

Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells
by: Eun-Nam Kim, et al.
Published: (2020)

Phosphorylation of BCL2 at the Ser70 site mediates RANKL-induced osteoclast precursor autophagy and osteoclastogenesis
by: Dianshan Ke, et al.
Published: (2022)

M2 macrophages-derived exosomes regulate osteoclast differentiation by the CSF2/TNF-α axis
by: Yue Zhou, et al.
Published: (2024)

Ac-SDKP Attenuates Activation of Lung Macrophages and Bone Osteoclasts in Rats Exposed to Silica by Inhibition of TLR4 and RANKL Signaling Pathways
by: Jin F, et al.
Published: (2021)

The Therapeutic Potential of Two Egyptian Plant Extracts for Mitigating Dexamethasone-Induced Osteoporosis in Rats: Nrf2/HO-1 and RANK/RANKL/OPG Signals
by: Samar R. Saleh, et al.
Published: (2024)

Monosodium Urate in the Presence of RANKL Promotes Osteoclast Formation through Activation of c-Jun N-Terminal Kinase
by: Jung-Yoon Choe, et al.
Published: (2015)

Inhibition of insulin degrading enzyme suppresses osteoclast hyperactivity via enhancing Nrf2-dependent antioxidant response in glucocorticoid-induced osteonecrosis of the femoral head
by: Tao Yuan, et al.
Published: (2024)

Dendrobium officinale Orchid Extract Prevents Ovariectomy-Induced Osteoporosis in Vivo and Inhibits RANKL-Induced Osteoclast Differentiation in Vitro
by: Qi Wang, et al.
Published: (2018)

Corrigendum: Dendrobium officinale Orchid Extract Prevents Ovariectomy-Induced Osteoporosis In Vivo and Inhibits RANKL-Induced Osteoclast Differentiation In Vitro
by: Qi Wang, et al.
Published: (2020)

CpG Oligodeoxynucleotides Inhibit RANKL-Induced Osteoclast Formation by Upregulating A20 Deubiquitinase in RAW 264.7 Cells
by: Seong-Kyu Kim, et al.
Published: (2022)

Nox4 Promotes RANKL-Induced Autophagy and Osteoclastogenesis via Activating ROS/PERK/eIF-2α/ATF4 Pathway
by: Jing Sun, et al.
Published: (2021)

Sitagliptin, An Anti-diabetic Drug, Suppresses Estrogen Deficiency-Induced OsteoporosisIn Vivo and Inhibits RANKL-Induced Osteoclast Formation and Bone Resorption In Vitro
by: Chuandong Wang, et al.
Published: (2017)

Genipin Inhibits RANKL-Induced Osteoclast Differentiation Through Proteasome-Mediated Degradation of c-Fos Protein and Suppression of NF-κB Activation
by: Chang Hoon Lee, et al.
Published: (2014)

Pantoprazole (PPZ) Inhibits RANKL-Induced Osteoclast Formation and Function In Vitro and Prevents Lipopolysaccharide- (LPS-) Induced Inflammatory Calvarial Bone Loss In Vivo
by: Yu-Xi Li, et al.
Published: (2020)

Puerarin inhibits the osteoclastogenesis by inhibiting RANKL-dependent and -independent autophagic responses
by: Guoyou Zhang, et al.
Published: (2019)

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
by: Li X, et al.
Published: (2021)

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways
by: Cong Wang, et al.
Published: (2024)

Ciprofloxacin and pegylated G-CSF combined therapy mitigates brain hemorrhage and mortality induced by ionizing irradiation
by: Juliann G. Kiang, et al.
Published: (2023)

A Novel BD2-Selective Inhibitor of BRDs Mitigates ROS Production and OA Pathogenesis
by: Hyemi Lee, et al.
Published: (2024)

Doxorubicin Induces Bone Loss by Increasing Autophagy through a Mitochondrial ROS/TRPML1/TFEB Axis in Osteoclasts
by: Hyun-Jung Park, et al.
Published: (2022)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
by: Qi He, et al.
Published: (2022)

Erratum to: Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells
by: Jeong-Mi Kim, et al.
Published: (2017)

CTRP9 Mitigates the Progression of Arteriovenous Shunt-Induced Pulmonary Artery Hypertension in Rats
by: Hua Guan, et al.
Published: (2021)

HO-1 Upregulation by Kaempferol via ROS-Dependent Nrf2-ARE Cascade Attenuates Lipopolysaccharide-Mediated Intercellular Cell Adhesion Molecule-1 Expression in Human Pulmonary Alveolar Epithelial Cells
by: Chien-Chung Yang, et al.
Published: (2022)

Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes
by: Leoni Lorenz, et al.
Published: (2024)

Dauricine Protects from LPS-Induced Bone Loss via the ROS/PP2A/NF-κB Axis in Osteoclasts
by: Hyun-Jung Park, et al.
Published: (2020)